BiomX Presenting at Two Upcoming Conferences in November

Rhea-AI Summary

BiomX Inc. (PHGE), a clinical-stage microbiome company, announced its participation in two upcoming healthcare events: the Jefferies London Healthcare Conference from November 18-19, 2021 and the 2021 Phage Futures Congress Europe on November 23-24, 2021. At the Jefferies conference, an on-demand session will be presented by Jonathan Solomon, available from November 18. The Phage Futures Congress will feature a presentation titled “Nebulized Bacteriophage Therapy” by Myriam Golembo, Ph.D. on November 23. Webcasts will be accessible via the company's website.

Jefferies London Healthcare Conference on November 18 - 19, 2021

2021 Phage Futures Congress Europe on November 23 - 24, 2021

NESS ZIONA, Israel, Nov. 17, 2021 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced upcoming presentations at the Jefferies London Healthcare Conference on November 18-19 and the 2021 Phage Futures Congress Europe on November 23-24.

Jefferies London Healthcare Conference – November 18-19, 2021
Date & Time:	On-demand session will be available to conference attendees beginning Thursday, November 18, 3:00 AM EST through November 19, 12:00 PM EST
Presenter:	Jonathan Solomon
Webcast Link:	Link
2021 Phage Futures Congress Europe – November 23-24, 2021
Presentation Title:	“Nebulized Bacteriophage Therapy for Chromic Pseudomonas aeruginosa Pulmonary Infections in CF Patients”
Date & Time:	November 23, 11:30 AM CET, 5:30 AM EST
Location	Brussels, Beligium
Presenter:	Myriam Golembo, Ph.D.

Live webcasts of the Jefferies London Healthcare Conference will be accessible through the Investors section of the Company’s website at https://ir.biomx.com/news-events/ir-calendar. Following the events, the webcasts will be archived on the BiomX website.

About BiomX Inc.

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria that affect the appearance of skin, as well as target bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets. For more information, please visit www.BiomX.com

BiomX Contacts

Investor Relations:
LifeSci Advisors, LLC
John Mullaly
(617)-698-9253
jmullaly@lifesciadvisors.com 

FAQ

What is BiomX's stock symbol and what is its focus?

BiomX's stock symbol is PHGE, and it focuses on developing phage therapies that target pathogenic bacteria.

When will BiomX present at the Jefferies London Healthcare Conference?

BiomX will present at the Jefferies London Healthcare Conference on November 18-19, 2021.

Who will present at the BiomX session during the Jefferies conference?

Jonathan Solomon will present during BiomX's session at the Jefferies conference.

What is the title of BiomX's presentation at the Phage Futures Congress Europe?

The title of BiomX's presentation at the Phage Futures Congress Europe is 'Nebulized Bacteriophage Therapy for Chronic Pseudomonas aeruginosa Pulmonary Infections in CF Patients'.

When and where will BiomX present at the Phage Futures Congress Europe?

BiomX will present on November 23, 2021, at 11:30 AM CET in Brussels, Belgium.